Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer

Chu, Michael P.; Hecht, J. Randolph; Slamon, Dennis J.; Wainberg, Zev A.; Bang, Yung Jue; Hoff, Paulo M.; Sobrero, Alberto F.; Qin, Shukui; Afenjar, Karen; Houé, Vincent; King, Karen L.; Koski, Sheryl; Mulder, Karen; Hiller, Julie Price; Scarfe, Andrew; Spratlin, Jennifer L.; Huang, Yingjie; Khan-Wasti, S.; Chua, Neil; Sawyer, Michael B.

doi:10.1001/jamaoncol.2016.3358

Cited by 92 publications

(121 citation statements)

References 21 publications

Supporting

Mentioning

115

Contrasting

Order By: Relevance

“…risk of myocardial infarction is higher in patients who have heart failure) and mortality which was obtained from a number of epidemiological studies. [41,42,43,44,45,46,47,48,49,50,51,52]. …”

Section: Methodsmentioning

confidence: 99%

Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling

Lucchese

Borisenko²,

Mantovani

et al. 2017

Obes Facts

View full text Add to dashboard Cite

Objective: To evaluate the cost-effectiveness of bariatric surgery in Italy from a third-party payer perspective over a medium-term (10 years) and a long-term (lifetime) horizon. Methods: A state-transition Markov model was developed, in which patients may experience surgery, post-surgery complications, diabetes mellitus type 2, cardiovascular diseases or die. Transition probabilities, costs, and utilities were obtained from the Italian and international literature. Three types of surgeries were considered: gastric bypass, sleeve gastrectomy, and adjustable gastric banding. A base-case analysis was performed for the population, the characteristics of which were obtained from surgery candidates in Italy. Results: In the base-case analysis, over 10 years, bariatric surgery led to cost increment of EUR 2,661 and generated additional 1.1 quality-adjusted life years (QALYs). Over a lifetime, surgery led to savings of EUR 8,649, additional 0.5 life years and 3.2 QALYs. Bariatric surgery was cost-effective at 10 years with an incremental cost-effectiveness ratio of EUR 2,412/QALY and dominant over conservative management over a lifetime. Conclusion: In a comprehensive decision analytic model, a current mix of surgical methods for bariatric surgery was cost-effective at 10 years and cost-saving over the lifetime of the Italian patient cohort considered in this analysis.

show abstract

Section: Methodsmentioning

confidence: 99%

Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling

Lucchese

Borisenko²,

Mantovani

et al. 2017

Obes Facts

View full text Add to dashboard Cite

show abstract

“…A total of 353 potentially eligible records were identified in the electronic databases. After exclusion of n=337 not pertinent papers, n=16 were selected for inclusion in quantitative analysis (n=372,418 patients included, with 12% of patients receiving concomitant GAS therapy) [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. The search results and characteristics of the included studies are presented in figure 1 and tables 1-2.…”

Section: Resultsmentioning

confidence: 99%

Impact of Use of Gastric-Acid Suppressants and Oral Anticancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis

Indini¹,

Petrelli²,

Tomasello³

et al. 2020

Preprint

View full text Add to dashboard Cite

We performed a systematic review and meta-analysis to evaluate the role of gastric acid suppressant use on outcomes of tyrosine kinase inhibitors (TKIs) and oral chemotherapy. We identified all researches evaluating the effect of GAS use on patients receiving oral chemotherapy or TKIs for solid tumors. The pooled hazard ratios (HRs) and 95% confidence interval (95% CI) for overall survival (OS) and progression-free survival (PFS) were calculated with fixed-effects or random-effects model. The study population included n=16 retrospective studies and 372,418 patients. Series concerned gastrointestinal tract tumors (n=5 studies), renal cell carcinomas (RCC, n=3 studies), non-small cell lung cancers (NSCLC, n=5 studies), and soft tissue sarcomas or mixed histologies solid tumors in n=3 studies. The pooled HRs for OS and PFS were 1.31 (95% CI: 1.20–1.43; P<01) and 1.3 (95%CI 1.07-1.57; P<0.01) for GAS and no GAS users, respectively. Only studies of EGFR mutated NSCLC patients receiving TKIs and those with colorectal cancer receiving oral chemotherapy showed a significant correlation between GAS and poor survival. Our study supports the evidence of a possible negative impact of concomitant GAS therapy on survival outcomes of patients receiving oral anti-cancer drugs.

show abstract

“…They reported that bevacizumab added to capecitabine with oxaliplatin is an active and well-tolerated regimen for patients with small bowel adenocarcinoma and ampullary adenocarcinoma. 4 In conclusion, the efficacy of capecitabine may be decreased during the concomitant use of PPIs by possibly raising gastric pH levels, thereby leading to alterations in the dissolution and absorption of capecitabine. 2,3 This association with gastric acid suppressants may not be limited to tyrosine kinase inhibitors given that many oral drugs such as capecitabine require a sufficiently acidic environment to properly dissolve for systemic absorption.…”

mentioning

confidence: 97%

“…The authors found that PPIs negatively affected the efficacy of capecitabine. 4 In conclusion, the efficacy of capecitabine may be decreased during the concomitant use of PPIs by possibly raising gastric pH levels, thereby leading to alterations in the dissolution and absorption of capecitabine. Therefore, patients being treated with capecitabine should be questioned as to whether they are receiving concomitant PPIs.…”

mentioning

confidence: 97%

“…2,3 This association with gastric acid suppressants may not be limited to tyrosine kinase inhibitors given that many oral drugs such as capecitabine require a sufficiently acidic environment to properly dissolve for systemic absorption. A recent study 4 investigated the association between PPIs and capecitabine efficacy in patients with advanced gastroesophageal cancer. Capecitabine appears to be sensitive to changes in the gastric pH level by which substantial reductions in gastric acidity can lead to less drug dissolution.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Coadministration of proton pump inhibitors and the efficacy of capecitabine in patients with advanced adenocarcinoma of the small bowel or ampulla of vater

Altundağ

2017

Cancer

View full text Add to dashboard Cite

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer

Abstract: clinicaltrials.gov Identifier: NCT00680901.

Cited by 92 publications

References 21 publications

Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling

Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling

Impact of Use of Gastric-Acid Suppressants and Oral Anticancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis

Coadministration of proton pump inhibitors and the efficacy of capecitabine in patients with advanced adenocarcinoma of the small bowel or ampulla of vater

Contact Info

Product

Resources

About